These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Brentuximab vedotin plus AVD followed by involved-node radiotherapy in a patient with classic Hodgkin lymphoma following gray zone lymphoma after autologous stem-cell transplantation failure. Ueda N; Kato H; Kato S; Saito T; Tachibana H; Yanada M; Taji H; Kodaira T; Hosoda W; Yamamoto K Hematology; 2023 Dec; 28(1):2207946. PubMed ID: 37183912 [TBL] [Abstract][Full Text] [Related]
3. [Brentuximab vedotin and immune checkpoint inhibitors for the treatment of Hodgkin lymphoma]. Maruyama D Rinsho Ketsueki; 2020; 61(8):890-900. PubMed ID: 32908053 [TBL] [Abstract][Full Text] [Related]
4. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817 [TBL] [Abstract][Full Text] [Related]
5. Brentuximab vedotin and its use in the treatment of advanced Hodgkin's lymphoma. Nikolaenko L; Nademanee A Future Oncol; 2020 Oct; 16(29):2273-2282. PubMed ID: 32677451 [TBL] [Abstract][Full Text] [Related]
6. Novel Therapies in the Treatment of Hodgkin Lymphoma. Andrade-Gonzalez X; Ansell SM Curr Treat Options Oncol; 2021 Mar; 22(5):42. PubMed ID: 33755826 [TBL] [Abstract][Full Text] [Related]
7. Sequencing novel agents in the treatment of classical Hodgkin lymphoma. Ferhanoglu B; Ozbalak M Expert Rev Hematol; 2023; 16(12):991-1015. PubMed ID: 37897182 [TBL] [Abstract][Full Text] [Related]
8. Hodgkin lymphoma: Focus on evolving treatment paradigms. Roswarski JL; Longo DL Best Pract Res Clin Haematol; 2023 Dec; 36(4):101510. PubMed ID: 38092470 [TBL] [Abstract][Full Text] [Related]
9. Methotrexate-associated Hodgkin Lymphoma in a Patient with Rheumatoid Arthritis Successfully Treated with Brentuximab Vedotin in Combination with Doxorubicin, Vinblastine, and Dacarbazine (BV+AVD). Sekiguchi Y; Iizuka H; Takizawa H; Sugimoto K; Sakajiri S; Inano T; Fukuda Y; Shirane S; Hamano Y; Tomita S; Izumi H; Okubo M; Nakamura N; Sawada T; Sekiguchi N; Noguchi M Intern Med; 2020 Sep; 59(17):2165-2171. PubMed ID: 32461524 [TBL] [Abstract][Full Text] [Related]
10. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation. Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998 [TBL] [Abstract][Full Text] [Related]
11. Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives. Prince HM; Hutchings M; Domingo-Domenech E; Eichenauer DA; Advani R Ann Hematol; 2023 Jan; 102(1):13-29. PubMed ID: 36512081 [TBL] [Abstract][Full Text] [Related]
12. Tumor Flare Reaction in a Classic Hodgkin Lymphoma Patient Treated With Brentuximab Vedotin and Tislelizumab: A Case Report. Zhu C; Zhao Y; Yu F; Huang W; Wu W; He J; Cai Z; He D Front Immunol; 2021; 12():756583. PubMed ID: 35095839 [TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL; Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562 [TBL] [Abstract][Full Text] [Related]
14. Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin's lymphoma: a phase II, non-randomized controlled trial. Hochberg J; Basso J; Shi Q; Klejmont L; Flower A; Bortfeld K; Harrison L; van de Ven C; Moorthy C; Islam H; Gerard P; Voss S; Cairo MS J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35584865 [TBL] [Abstract][Full Text] [Related]
15. [Treatment strategy for newly diagnosed Hodgkin lymphoma: current evidence]. Kusumoto S Rinsho Ketsueki; 2018; 59(10):2117-2126. PubMed ID: 30305517 [TBL] [Abstract][Full Text] [Related]
16. Successful reversal of severe liver function impairment with Brentuximab vedotin in multiply relapsed/refractory classical Hodgkin lymphoma. Spathas N; Belia M; Giannikos T; Arapaki M; Efstathopoulou M; Tsourouflis G; Gainaru G; Asimakopoulos J; Tsaftaridis P; K Angelopoulou M; Plata E; Konstantopoulos K; P Vassilakopoulos T J BUON; 2019; 24(6):2483-2489. PubMed ID: 31983123 [TBL] [Abstract][Full Text] [Related]